Trials Sponsors Conditions Drugs Pricing

Conditions

Tumor, Solid, FAPI, PET/CT, Metastasis

Keywords

Diagnosis, Tumor, Solid, FAPI, PET/CT, Metastasis

Outcome Measures

Primary Outcomes (1)

Standardized uptake value (SUV)
Standardized uptake value (SUV) of 68Ga-DOTA-FAPI-46 / 68Ga-DOTA-2P(FAPI)2 for each primary tumor of subject or suspected lymph metastasis.
30 days

Secondary Outcomes (6)

Sensitivity
30 days
Specificity
30 days
The positive predictive value (PPV)
30 days
The negative predictive value (NPV)
30 days
The accuracy
30 days
+1 more secondary outcomes

Study Arms (1)

68Ga-DOTA-2P(FAPI)2 PET/CT

EXPERIMENTAL

Each subject receive a single intravenous injection of and 68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2, and undergo PET/CT imaging within the specified time.

Diagnostic Test: 68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2 PET/CT

Interventions

68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2 PET/CTDiagnostic test

Each subject receive a single intravenous injection of 68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2, and undergo PET/CT imaging within the specified time.

68Ga-DOTA-2P(FAPI)2 PET/CT

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 90 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

(i) adult patients (aged 18 years or order);
(ii) patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include magnetic resonance imaging (MRI), CT, tumor markers and pathology report);

Sponsors & Collaborators

The First Affiliated Hospital of Xiamen University
Otherlead

Study Sites (1)

The First affiliated hospital of xiamen university

Xiamen, Fujian, 361003, China

MeSH Terms

Conditions

NeoplasmsNeoplasm MetastasisDisease

Condition Hierarchy (Ancestors)

Neoplastic ProcessesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

Long Sun, PhD
The First Affiliated Hospital of Xiamen University
STUDY DIRECTOR

Enrollment

7 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: not applicable
Allocation: NA
Masking: NONE
Purpose: DIAGNOSTIC
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

June 20, 2021

First Posted

June 28, 2021

Study Start

June 18, 2021

Actual (reported)

Comparison of 68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2 PET/CT in Patients With Various Types of Cancer

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (6)

Study Arms (1)

68Ga-DOTA-2P(FAPI)2 PET/CT

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (6)

Study Arms (1)

68Ga-DOTA-2P(FAPI)2 PET/CT

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations